journal contribution
posted on 2023-03-31, 18:43 authored by Cesar A. Santa-Maria, Amanda Blackford, Anne T. Nguyen, Todd C. Skaar, Santosh Philips, Steffi Oesterreich, James M. Rae, Zeruesenay Desta, Jason Robarge, Norah Lynn Henry, Anna M. Storniolo, Daniel F. Hayes, Roger S. Blumenthal, Pamela Ouyang, Wendy S. Post, David A. Flockhart, Vered Stearns <p>Supplementary table 1. Findings of multivariable linear regressions analyzing genetic associations between candidate gene SNPs and lipid profiles in exemestane-treated participants complementary to statistically significant findings in letrozole-treated participants. Supplementary table 2. Findings of multivariable linear regressions analyzing genetic associations between candidate gene SNPs and lipid profiles in only Caucasian women taking both letrozole and exemestane complementary to statistically significant findings in letrozole-treated participants. *new significant finding (in letrozole only), and corresponding data for exemestane (additive rs1062033 and dominant rs1062033 models were not included due to number of homozygotes <5) Supplementary table 3. Significant findings of multivariable linear regressions analyzing genetic associations between candidate gene SNPs and lipid profiles without adjusting for changes in plasma estradiol concentrations.</p>
Funding
NIH/NIGMS Pharmacogenetics Network
Pfizer, Novartis, the Breast Cancer Research Foundation
NIH
Fashion Footwear Charitable Foundation of New York/QVC
Breast Cancer Research Chair in Oncology
History
ARTICLE ABSTRACT
Purpose: Aromatase inhibitors can exert unfavorable effects on lipid profiles; however, previous studies have reported inconsistent results. We describe the association of single-nucleotide polymorphisms (SNP) in candidate genes with lipid profiles in women treated with adjuvant aromatase inhibitors.Experimental Design: We conducted a prospective observational study to test the associations between SNPs in candidate genes in estrogen signaling and aromatase inhibitor metabolism pathways with fasting lipid profiles during the first 3 months of aromatase inhibitor therapy in postmenopausal women with early breast cancer randomized to adjuvant letrozole or exemestane. We performed genetic association analysis and multivariable linear regressions using dominant, recessive, and additive models.Results: A total of 303 women had complete genetic and lipid data and were evaluable for analysis. In letrozole-treated patients, SNPs in CYP19A1, including rs4646, rs10046, rs700518, rs749292, rs2289106, rs3759811, and rs4775936 were significantly associated with decreases in triglycerides by 20.2 mg/dL and 39.3 mg/dL (P < 0.00053), respectively, and with variable changes in high-density lipoprotein (HDL-C) from decreases by 4.2 mg/dL to increases by 9.8 mg/dL (P < 0.00053).Conclusions: Variants in CYP19A1 are associated with decreases in triglycerides and variable changes in HDL-C in postmenopausal women on adjuvant aromatase inhibitors. Future studies are needed to validate these findings, and to identify breast cancer survivors who are at higher risk for cardiovascular disease with aromatase inhibitor therapy. Clin Cancer Res; 22(6); 1395–402. ©2015 AACR.
